CME-accredited webinar | Interdisciplinary guidelines for myotonic dystrophy type 1 (DM1) management across the spectrum
NMD4C and Muscular Dystrophy Canada (MDC) are pleased to invite you to a webinar on interdisciplinary guidelines for myotonic dystrophy type 1 (DM1).
This webinar is CME-accredited. The NMD Rounds & Educational Webinars is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
This webinar is primarily targeted at Canadian clinicians, academics and trainees with an interest in neuromuscular disease. NMD4C and MDC are providing organizational and technical support, and this is an independent clinical/academic webinar with no industry sponsorship.
Tuesday, October 6th at 5:00pm ET
If you have any questions, please email
Register HERE
Objectives:
At the end of the presentation, the attendees will be able to identify:
- Key management areas among the most frequent phenotypes of DM1
- Key treatment perspectives in DM1
- Life-threatening complications related to DM1 management
Topics and speakers:
International clinical guidelines for adult DM1: An allied health perspective
Dr. Cynthia Gagnon (NMD4C investigator)
Exercise prescription for adult DM1: What do we know?
Dr. Élise Duchesne (NMD4C member)
International clinical guidelines for congenital DM1
Dr. Craig Campbell (NMD4C investigator) and Dr. Cam-Tu Nguyen
Read next...
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.
New Best Practice Recommendations for SBMA Care in Canada
Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!
Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting
On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.
NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders
On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.
2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!
Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)
Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients
We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.